inhibiting dkk1 enhances sorafenib efficacy in hcc
Published 10 months ago • 33 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
2:22
regorafenib and pd-1 inhibitor for a sorafenib-refractory hcc patient - video abstract [id 284092]
-
6:51
hcc: use of lenvatinib and sorafenib
-
2:01
qol analyses from rationale-301 of tislelizumab vs sorafenib in hcc
-
3:05
imbrave150: updated data on atezo plus bev versus sorafenib in hcc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
56:09
dr.charles dinarello_ il-1 as the master cytokine for inflammatory diseases
-
58:35
iskemia dan infark - dr. hendry purnasidha bagaswoto, sp.jp(k)
-
48:36
a vaccine for type 1 diabetes with diamyd medical's dr. ulf hannelius
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
2:12
hepatocellular carcinoma: immunotherapy after sorafenib
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
1:38
dr. abou-alfa on adjuvant sorafenib for the treatment of hcc (phase iii storm trial)
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
2:53
a patient with hepatocellular carcinoma (hcc) treated with nivolumab (opdivo) post sorafenib
-
0:54
jak1 inhibition enhances pembrolizumab efficacy in pd-l1 positive mnsclc
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
5:40
sorafenib initiation after tace in hcc
-
0:54
treatment landscape for hepatocellular carcinoma evolves at rapid pace
-
1:11
regorafenib vs sorafenib in the treatment of liver cancer
-
1:42
sirt versus sorafenib in locally advanced hepatocellular carcinoma (sirvenib study)